$3995 | Single User
$7990 | Site License
$11985 | Enterprise License

EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024

Published by Global Data: 01 Jan 2016 | 17999 | In Stock

Introduction

EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024

Summary

Pulmonary Arterial Hypertension (PAH) is a rare and severe condition characterized by vascular proliferation and remodeling of the small pulmonary arteries. This results in progressively increasing pulmonary vascular resistance, leading to an increase in pulmonary arterial pressure. The disease typically results in right-sided heart failure and premature death. PAH can be idiopathic, heritable, or associated with different conditions such as connective tissue disease (CTD), congenital heart disease (CHD), human immunodeficiency virus (HIV) infection, and exposure to toxins or drugs. PAH occurs twice as frequently in women as in men.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of PAH in the 7MM, from 1,769 diagnosed incident cases in 2014 to 1,838 diagnosed incident cases in 2024, with an Annual Growth Rate (AGR) of 0.39% during the forecast period. In 2024, the US will have the highest number of diagnosed incident cases of PAH in the 7MM, with 677 diagnosed incident cases, whereas the UK will have the lowest number of diagnosed incident cases of PAH, with 74 diagnosed incident cases. Similarly, the diagnosed prevalent cases of PAH in the 7MM are expected to increase from 9,926 diagnosed prevalent cases in 2014 to 10,285 diagnosed prevalent cases in 2024, with an AGR of 0.36% during the forecast period. In 2024, the US will have the highest number of diagnosed prevalent cases of PAH in the 7MM, with 4,325 diagnosed prevalent cases, whereas the UK will have the lowest number of diagnosed prevalent cases of PAH, with 443 diagnosed prevalent cases.

GlobalData’s epidemiological forecast for the diagnosed incident and the diagnosed prevalent cases of PAH in the 7MM is supported by age- and sex-specific data. The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the projected diagnosed incident cases and diagnosed prevalent cases of PAH across the markets. Additionally, GlobalData epidemiologists provided the diagnosed prevalent cases of PAH in each of the 7MM, segmented by the NYHA functional class I-IV, which is an important factor for predicting the prognosis, as well as the need for various clinical and treatment modalities specific to the functional classes, for PAH. GlobalData epidemiologists also provide an additional forecast for the diagnosed incident and diagnosed prevalent cases of PAH, adjusted for the underestimation of registry based forecast. These two different types of forecast strengthen the analysis, and present a comparative assessment of the extent of underestimation when using registry based data, which can be evaluated to provide better insights on the burden of the condition.

Scope

- The Pulmonary Arterial Hypertension (PAH) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for RSV infection in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed incident cases and diagnosed prevalent cases of PAH, segmented by sex, and age (in 10-year increments beginning at 0 years and ending at =85 years in these markets.

- The PAH epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

The PAH EpiCast report will allow you to -

- Develop business strategies by understanding the trends shaping and driving the global PAH market.

- Quantify patient populations in the global PAH market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for PAH therapeutics in each of the markets covered.

Table of Contents
for EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024

  • 1 Table of Contents

    1 Table of Contents 5

    1.1 List of Tables 6

    1.2 List of Figures 7

    2 Introduction 9

    2.1 Catalyst 9

    2.2 Related Reports 10

    2.3 Upcoming Reports 11

    3 Epidemiology 12

    3.1 Disease Background 12

    3.2 Risk Factors and Comorbidities 14

    3.3 Global Trends 15

    3.3.1 Incidence and Prevalence 15

    3.4 Forecast Methodology 17

    3.4.1 Sources Used 20

    3.4.2 Sources Not Used 25

    3.4.3 Forecast Assumptions and Methods 26

    3.5 Epidemiological Forecast for PAH (2014-2024) 32

    3.5.1 Epidemiological Forecast for PAH - Based on Registry Data 33

    3.5.2 Epidemiological Forecast for PAH - Adjusted for Underestimation 47

    3.6 Discussion 60

    3.6.1 Epidemiological Forecast Insight 60

    3.6.2 Limitations of the Analysis 61

    3.6.3 Strengths of the Analysis 62

    4 Appendix 64

    4.1 Bibliography 64

    4.2 About the Authors 67

    4.2.1 Epidemiologists 67

    4.2.2 Reviewers 67

    4.2.3 Global Director of Therapy Analysis and Epidemiology 68

    4.2.4 Global Head of Healthcare 69

    4.3 About GlobalData 70

    4.4 About EpiCast 70

    4.5 Disclaimer 71

List Of Tables
in EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024

1.1 List of Tables

Table 1: WHO Guidelines, Modified New York Heart Association Functional Classes I-IV 13

Table 2: Risk Factors and Comorbidities for PAH 14

Table 3: 7MM, Global Trends for the Diagnosed Incidence of PAH 16

Table 4: 7MM, Global Trends for the Diagnosed Prevalence of PAH 17

Table 5: 7MM Sources of Epidemiological Data Used for the Forecast for PAH Diagnosed Incident Cases (Based on Registry Data) 18

Table 6: 7MM Sources of Epidemiological Data Used for the Forecast for PAH Diagnosed Prevalent Cases (Based on Registry Data) 19

Table 7: 7MM Sources of Epidemiological Data Used for the Classification of Diagnosed Prevalent Cases* According to the NYHA Functional Classes I-IV 20

Table 8: 7MM, Diagnosed Incident Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Based on Registry Data) 33

Table 9: 7MM, Age-Specific Diagnosed Incident Cases of PAH, Both Sexes, N (Row %), 2014 (Based on Registry Data) 35

Table 10: 7MM, Sex-Specific Diagnosed Incident Cases of PAH, All Ages, N (Row %), 2014 (Based on Registry Data) 37

Table 11: 7MM, Diagnosed Prevalent Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Based on Registry Data) 40

Table 12: 7MM Age-Specific Diagnosed Prevalent Cases of PAH, Both Sexes, N (Row %), 2014 (Based on Registry Data) 42

Table 13: 7MM, Sex-Specific Diagnosed Prevalent Cases of PAH, All Ages, N (Row %), 2014 (Based on Registry Data) 44

Table 14: 7MM, Diagnosed Incident Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Adjusted for Underestimation) 48

Table 15: 7MM, Age-Specific Diagnosed Incident Cases of PAH, Both Sexes, N (Row %), 2014 (Adjusted for Underestimation) 50

Table 16: 7MM, Sex-Specific Diagnosed Incident Cases of PAH, All Ages, N (Row %), 2014 (Adjusted for Underestimation) 52

Table 17: 7MM, Diagnosed Prevalent Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Adjusted for Underestimation) 54

Table 18: 7MM, Age-Specific Diagnosed Prevalent Cases of PAH, Both Sexes, N (Row %), 2014 (Adjusted for Underestimation) 56

Table 19: 7MM, Sex-Specific Diagnosed Prevalent Cases of PAH, All Ages, N (Row %), 2014 (Adjusted for Underestimation) 58

List Of Figures, Charts and Diagrams
in EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024

1.2 List of Figures

Figure 1: 7MM, Diagnosed Incident Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Based on Registry Data) 34

Figure 2: 7MM, Age-Specific Diagnosed Incident Cases of PAH, Both Sexes, N, 2014 (Based on Registry Data) 36

Figure 3: 7MM, Sex-Specific Diagnosed Incident Cases of PAH, All Ages, N, 2014 (Based on Registry Data) 38

Figure 4: 7MM, Age-Standardized Diagnosed Incidence of PAH (Cases per 100,000 Population), All Ages, by Sex, 2014 (Based on Registry Data) 39

Figure 5: 7MM, Diagnosed Prevalent Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Based on Registry Data) 40

Figure 6: 7MM Age-Specific Diagnosed Prevalent Cases of PAH, Both Sexes, N, 2014 (Based on Registry Data) 43

Figure 7: 7MM, Sex-Specific Diagnosed Prevalent Cases of PAH, All Ages, N, 2014 (Based on Registry Data) 45

Figure 8: 7MM, Age-Standardized Diagnosed Prevalence of PAH (%), All Ages, by Sex, 2014 (Based on Registry Data) 46

Figure 9: 7MM, Diagnosed Prevalent Cases of PAH Categorized into NYHA Functional Classes (N), All Ages, 2014 (Based on Registry Data) 47

Figure 10: 7MM, Diagnosed Incident Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Adjusted for Underestimation) 48

Figure 11: 7MM, Age-Specific Diagnosed Incident Cases of PAH, Both Sexes, N, 2014 (Adjusted for Underestimation) 51

Figure 12: 7MM, Sex-Specific Diagnosed Incident Cases of PAH, All Ages, N, 2014 (Adjusted for Underestimation) 53

Figure 13: 7MM, Diagnosed Prevalent Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Adjusted for Underestimation) 54

Figure 14: 7MM, Age-Specific Diagnosed Prevalent Cases of PAH, Both Sexes, N, 2014 (Adjusted for Underestimation) 57

Figure 15: 7MM, Sex-Specific Diagnosed Prevalent Cases of PAH, All Ages, N, 2014 (Adjusted for Underestimation) 59

Figure 16: 7MM, Diagnosed Prevalent Cases of PAH Categorized into NYHA Functional Classes (N), All Ages, 2014 (Adjusted for Underestimation) 60

Additional Details

Publisher

Global Data

Publisher Information

Reference

17999 | GDHCER114-15

Number of Pages

72

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024
EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024SummaryNon-Hodgkin’s Lymphoma ...
01 Jan 2016 by Global Data USD $3,995 More Info
EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024
EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024SummarySmall Cell Lung Cancer ...
01 Jan 2016 by Global Data USD $3,995 More Info
EpiCast Report: Vasculitis - Epidemiology Forecast to 2024
EpiCast Report: Vasculitis - Epidemiology Forecast to 2024SummaryVasculitis is a group of heterogene...
01 Jan 2016 by Global Data USD $3,995 More Info
EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024
EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024SummaryThe Hepatitis B Virus (HBV...
24 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024
EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024SummaryRSV is a...
23 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024
EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024SummarySjögren’s syndrome (SS) is ...
09 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024
EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024SummaryHuntington’s disease (HD)...
09 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024
EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024SummarySystemic scle...
09 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023
EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023SummaryC...
01 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024
EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024SummaryPrimary brain cancer is defined a...
01 Dec 2015 by Global Data USD $3,995 More Info

This report is published by Global Data

Download Free Report Summary PDF

EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data